Drug Description in Trials / DrugBank / KEGG DRUG

  

Search results

No. 薬物名（臨床試験情報から抽出） DrugBank KEGG DRUG KEGG GENES KEGG PATHWAY 指定難病告示番号
1Other:----2件: 2, 65
2Other: 0 mg----1件: 97
3Other: 0.02% Fm, SH, tBCL----1件: 53
4Other: 0.9% sodium chloride2件: Chloride ion,
Sodium chloride		1件: D02056 --1件: 65
5Other: 0.9ml sodium chloride2件: Chloride ion,
Sodium chloride		1件: D02056 --1件: 271
6Other: 1 Food Elimination Diet----1件: 98
7Other: 1 Food Elimination Diet Therapy----1件: 98
8Other: 100% pomegranate juice1件: Pomegranate---2件: 96, 97
9Other: 13C6 Leucine1件: Leucine1件: D00030 --3件: 5, 7, 127
10Other: 18F-FDG1件: Fludeoxyglucose (18F)---2件: 46, 84
11Other: 18F-FDG PET/CT1件: Fludeoxyglucose (18F)---1件: 41
12Other: 18F-Fluorodeoxyglucose (18F-FDG) PET/CT1件: Fludeoxyglucose (18F)---1件: 84
13Other: 18F-GE-1801件: Flutriciclamide F-18---1件: 46
14Other: 2h standardized aerobic exercise----1件: 78
15Other: 3-days water-fasting1件: Water1件: D00001 --1件: 67
16Other: 31-Phosphorus RMN Spectroscopy1件: Phosphorus---1件: 8
17Other: 4 Food Elimination Diet----1件: 98
18Other: 4 Food Elimination Diet (post 1FED failure)----1件: 98
19Other: 5-ASA Withdrawal1件: Mesalazine1件: D00377 --1件: 96
20Other: 6 Food Elimination Diet (after 1FED failure)----1件: 98
21Other: 6 Food Elimination Diet Therapy----1件: 98
22Other: 60% Oxygen1件: Oxygen1件: D00003 --1件: 85
23Other: [11C]-Methionine PET/MRI1件: Methionine2件: D00019 ,
D04983 		--1件: 75
24Other: [11C]donepezil PET1件: Donepezil2件: D00670 ,
D07869 		1件: ACHE 💬2件: Cholinergic synapse, Glycerophospholipid metabolism 💬1件: 6
25Other: A-STEP----1件: 299
26Other: A-STEP (New Protocol)----1件: 299
27Other: Abdominal compression----1件: 17
28Other: Absorptive clearance scan----1件: 299
29Other: Acute response to high-impact exercise----1件: 96
30Other: Ad libitum water intake1件: Water1件: D00001 --1件: 67
31Other: Adalimumab1件: Adalimumab1件: D02597 1件: TNF 💬67件: AGE-RAGE signaling pathway in diabetic complications, Adipocytokine signaling pathway, African trypanosomiasis, Alcoholic liver disease, Allograft rejection, Alzheimer disease, Amoebiasis, Amyotrophic lateral sclerosis, Antifolate resistance, Antigen processing and presentation, Apoptosis, Asthma, C-type lectin receptor signaling pathway, Chagas disease, Coronavirus disease - COVID-19, Cytokine-cytokine receptor interaction, Dilated cardiomyopathy, Epstein-Barr virus infection, Fc epsilon RI signaling pathway, Fluid shear stress and atherosclerosis, Graft-versus-host disease, Hematopoietic cell lineage, Hepatitis B, Hepatitis C, Herpes simplex virus 1 infection, Human T-cell leukemia virus 1 infection, Human cytomegalovirus infection, Human immunodeficiency virus 1 infection, Human papillomavirus infection, Hypertrophic cardiomyopathy, IL-17 signaling pathway, Inflammatory bowel disease, Influenza A, Insulin resistance, Legionellosis, Leishmaniasis, Lipid and atherosclerosis, MAPK signaling pathway, Malaria, NF-kappa B signaling pathway, NOD-like receptor signaling pathway, Natural killer cell mediated cytotoxicity, Necroptosis, Non-alcoholic fatty liver disease, Osteoclast differentiation, Pathogenic Escherichia coli infection, Pathways of neurodegeneration - multiple diseases, Pertussis, Prion disease, Proteoglycans in cancer, RIG-I-like receptor signaling pathway, Rheumatoid arthritis, Salmonella infection, Shigellosis, Sphingolipid signaling pathway, Systemic lupus erythematosus, T cell receptor signaling pathway, TGF-beta signaling pathway, TNF signaling pathway, Toll-like receptor signaling pathway, Toxoplasmosis, Tuberculosis, Type I diabetes mellitus, Type II diabetes mellitus, Viral protein interaction with cytokine and cytokine receptor, Yersinia infection, mTOR signaling pathway 💬1件: 46
32Other: Adalimumab treatment1件: Adalimumab1件: D02597 1件: TNF 💬67件: AGE-RAGE signaling pathway in diabetic complications, Adipocytokine signaling pathway, African trypanosomiasis, Alcoholic liver disease, Allograft rejection, Alzheimer disease, Amoebiasis, Amyotrophic lateral sclerosis, Antifolate resistance, Antigen processing and presentation, Apoptosis, Asthma, C-type lectin receptor signaling pathway, Chagas disease, Coronavirus disease - COVID-19, Cytokine-cytokine receptor interaction, Dilated cardiomyopathy, Epstein-Barr virus infection, Fc epsilon RI signaling pathway, Fluid shear stress and atherosclerosis, Graft-versus-host disease, Hematopoietic cell lineage, Hepatitis B, Hepatitis C, Herpes simplex virus 1 infection, Human T-cell leukemia virus 1 infection, Human cytomegalovirus infection, Human immunodeficiency virus 1 infection, Human papillomavirus infection, Hypertrophic cardiomyopathy, IL-17 signaling pathway, Inflammatory bowel disease, Influenza A, Insulin resistance, Legionellosis, Leishmaniasis, Lipid and atherosclerosis, MAPK signaling pathway, Malaria, NF-kappa B signaling pathway, NOD-like receptor signaling pathway, Natural killer cell mediated cytotoxicity, Necroptosis, Non-alcoholic fatty liver disease, Osteoclast differentiation, Pathogenic Escherichia coli infection, Pathways of neurodegeneration - multiple diseases, Pertussis, Prion disease, Proteoglycans in cancer, RIG-I-like receptor signaling pathway, Rheumatoid arthritis, Salmonella infection, Shigellosis, Sphingolipid signaling pathway, Systemic lupus erythematosus, T cell receptor signaling pathway, TGF-beta signaling pathway, TNF signaling pathway, Toll-like receptor signaling pathway, Toxoplasmosis, Tuberculosis, Type I diabetes mellitus, Type II diabetes mellitus, Viral protein interaction with cytokine and cytokine receptor, Yersinia infection, mTOR signaling pathway 💬1件: 151
33Other: Additional Therapies----1件: 97
34Other: Air - oxygen1件: Oxygen1件: D00003 --1件: 299
35Other: Aminoacid, alanine-infusion1件: Alanine1件: D00012 --1件: 251
36Other: Amyotrophic Lateral Sclerosis Functional Rating Scale-Revised----1件: 2
37Other: Antigen (wheat base soy sauce) spray1件: Wheat1件: D06902 --1件: 98
38Other: anxiety----1件: 13
39Other: Assessment of medication compliance----1件: 98
40Other: At-home natalizumab treated MS patient1件: Natalizumab1件: D06886 1件: ITGA4 💬14件: Arrhythmogenic right ventricular cardiomyopathy, Cell adhesion molecules, Dilated cardiomyopathy, ECM-receptor interaction, Focal adhesion, Hematopoietic cell lineage, Human papillomavirus infection, Hypertrophic cardiomyopathy, Intestinal immune network for IgA production, Leishmaniasis, Leukocyte transendothelial migration, PI3K-Akt signaling pathway, Regulation of actin cytoskeleton, Yersinia infection 💬1件: 13
41Other: Autogenic drainage----1件: 299
42Other: Autologous Platelet rich plasma----1件: 35
43Other: autologous serum and rebamipide 2%1件: Rebamipide1件: D01121 --1件: 53
44Other: Avise PG - Diagnostic test----1件: 46
45Other: Balance1件: Isoxaflutole---3件: 6, 13, 299
46Other: Balance exercise1件: Isoxaflutole---1件: 6
47Other: Balance exercise program using exoskeleton device1件: Isoxaflutole---1件: 13
48Other: Balance exercises1件: Isoxaflutole---1件: 13
49Other: Balance Trainer Balance Exercises1件: Isoxaflutole---1件: 13
50Other: Balance Training1件: Isoxaflutole---2件: 6, 13
51Other: Baseline serum vitamin D level at or above 50 nmol/l1件: Vitamin D---1件: 46
52Other: Baseline serum vitamin D level below 50 nmol/l1件: Vitamin D---1件: 46
53Other: beetroot juice extract----1件: 113
54Other: Berg Balance Scale1件: Isoxaflutole---2件: 6, 13
55Other: Best Medical Treatment----1件: 6
56Other: Best Practice----1件: 60
57Other: Biological samples----1件: 206
58Other: Biopsy----1件: 51
59Other: Blood analysis for frataxin's level measurement----1件: 18
60Other: Blood collection for measurement of eculizumab peak concentrations1件: Eculizumab1件: D03940 1件: C5 💬10件: Alcoholic liver disease, Complement and coagulation cascades, Coronavirus disease - COVID-19, Herpes simplex virus 1 infection, Neuroactive ligand-receptor interaction, Neutrophil extracellular trap formation, Pertussis, Prion disease, Staphylococcus aureus infection, Systemic lupus erythematosus 💬1件: 62
61Other: Blood drawing only Group C----1件: 49
62Other: Blood draws----3件: 49, 51, 85
63Other: Blood glucose results1件: Dextrose, unspecified form---1件: 299
64Other: blood sample----1件: 299
65Other: Blood sample and cotton skin swabs1件: Cotton---1件: 162
66Other: Blood samples----1件: 93
67Other: Blood sampling for Laboratory Developed Test (LDT) analysis----1件: 65
68Other: Blood test----2件: 83, 96
69Other: Blood-flow restricted training----1件: 15
70Other: BMI greater than or equal to 30kg/m2 scheduled for PSG. Undergo blood draw (arterial blood gas and metabolic panel) and data collection from PSG study.----1件: 230
71Other: BMI greater than or equal to 30kg/m2 scheduled for PSG. Undergo blood draw (venous blood gas and metabolic panel) and data collection from PSG study.----1件: 230
72Other: Bone Marrow aspiration----1件: 2
73Other: Bone Marrow Cell Transplantation----1件: 274
74Other: Brain MRI (magnetic resonance imaging)----1件: 17
75Other: Brief Pain Inventory questionnaire----1件: 19
76Other: Bronchoalveolar samples----1件: 51
77Other: BSC----1件: 85
78Other: Caffeine1件: Caffeine2件: D00528 ,
D01453 		11件: ADORA1,
ADORA2A,
PDE1B,
PDE2A,
PDE3A,
PDE3B,
PDE4A,
PDE4B,
PDE4C,
PDE4D,
PDE5A 💬		22件: Alcoholism, Aldosterone synthesis and secretion, Apelin signaling pathway, Calcium signaling pathway, Glucagon signaling pathway, Insulin signaling pathway, Metabolic pathways, Morphine addiction, Neuroactive ligand-receptor interaction, Olfactory transduction, Parathyroid hormone synthesis, secretion and action, Parkinson disease, Progesterone-mediated oocyte maturation, Purine metabolism, Rap1 signaling pathway, Regulation of lipolysis in adipocytes, Renin secretion, Sphingolipid signaling pathway, Taste transduction, Vascular smooth muscle contraction, cAMP signaling pathway, cGMP-PKG signaling pathway 💬1件: 13
79Other: Calcium stable isotope1件: Calcium---1件: 186
80Other: Carbon monoxide-bubbled mediums2件: Activated charcoal,
Carbon monoxide		1件: D09706 --1件: 298
81Other: carboxy methyl cellulose2件: Methylcellulose,
Microcrystalline cellulose		2件: D00093 ,
D04996 		--1件: 53
82Other: Cardiopulmonary evaluation----1件: 13
83Other: Cawthorne Cooksey exercises----1件: 13
84Other: CD LFD----1件: 96
85Other: CD-TREAT diet----1件: 96
86Other: Challenge agent: capsaicin1件: Capsaicin1件: D00250 1件: TRPV1 💬2件: Inflammatory mediator regulation of TRP channels, Neuroactive ligand-receptor interaction 💬1件: 19
87Other: Classic, progressive endurance training----1件: 13
88Other: Clinical data collection----3件: 49, 51, 85
89Other: clinical observation----1件: 205
90Other: CoA-Z----1件: 120
91Other: Coaching Sessions----1件: 49
92Other: CoDuSe balance training and step square exercises1件: Isoxaflutole---1件: 13
93Other: Coffee1件: Arabica coffee bean---1件: 96
94Other: Cognitive training----1件: 206
95Other: Colchicine Cessation1件: Colchicine1件: D00570 9件: TUBB,
TUBB1,
TUBB2A,
TUBB2B,
TUBB3,
TUBB4A,
TUBB4B,
TUBB6,
TUBB8 💬		10件: Alzheimer disease, Amyotrophic lateral sclerosis, Gap junction, Huntington disease, Parkinson disease, Pathogenic Escherichia coli infection, Pathways of neurodegeneration - multiple diseases, Phagosome, Prion disease, Salmonella infection 💬1件: 266
96Other: collection of CSF, blood, urine, saliva----1件: 6
97Other: Communicative Effectiveness Survey----1件: 2
98Other: Comparator: CPET cycle ergometer (Gold Standard)1件: Gold---1件: 299
99Other: Computer game based balance and walking rehabilitation for individuals with Parkinson's Disease1件: Isoxaflutole---1件: 6
100Other: Concomitant Medication----1件: 49
101Other: Continuation of dornase alfa (dnase)1件: Dornase alfa1件: D03896 --1件: 299
102Other: Continuation of hypertonic saline (HS)----1件: 299
103Other: continue their usual therapy----1件: 66
104Other: Control----9件: 6, 19, 67, 70, 75, 85, 97, 162, 193
105Other: Control Diet----1件: 96
106Other: Control group----1件: 2
107Other: Control group(Normal saline)----1件: 97
108Other: Control wound treatment----1件: 36
109Other: Controlled environment tests (series of tasks of everyday life)----1件: 6
110Other: Controls Primary Cervical Dystonia (Trihexyphenidyl)1件: Trihexyphenidyl2件: D00787 ,
D08638 		5件: CHRM1,
CHRM2,
CHRM3,
CHRM4,
CHRM5 💬		13件: Alzheimer disease, Calcium signaling pathway, Cholinergic synapse, Gastric acid secretion, Insulin secretion, Neuroactive ligand-receptor interaction, PI3K-Akt signaling pathway, Pancreatic secretion, Pathways of neurodegeneration - multiple diseases, Regulation of actin cytoskeleton, Salivary secretion, Taste transduction, cAMP signaling pathway 💬1件: 6
111Other: conventional balance training1件: Isoxaflutole---1件: 13
112Other: Conventional drugs----1件: 97
113Other: Conventional PCA mode----1件: 70
114Other: Conventional physiotherapy----1件: 6
115Other: Core stability----1件: 13
116Other: corn starch1件: Starch, corn1件: D05297 --1件: 49
117Other: corticotropin releasing hormone (CRH)1件: Corticotropin1件: D00146 1件: MC2R 💬5件: Aldosterone synthesis and secretion, Cortisol synthesis and secretion, Cushing syndrome, Neuroactive ligand-receptor interaction, cAMP signaling pathway 💬1件: 78
118Other: Cough monitor1件: Methamidophos---1件: 85
119Other: Covid-19 vaccine----1件: 13
120Other: Crohn's disease exclusion diet (CDED)----1件: 96
121Other: Crohn's Disease TReatment-with-EATing diet (CD-TREAT diet)----1件: 96
122Other: Crohns Disease Exclusion Diet----1件: 96
123Other: Cultured Thymus Tissue Implantation and Parental Parathyroid Transplantation----1件: 65
124Other: Cultured Thymus Tissue Implantation with Parathyroid Transplantation----1件: 65
125Other: current treatment----1件: 46
126Other: cyclosporin A1件: Cyclosporine1件: D00184 5件: PPP3CA,
PPP3CB,
PPP3CC,
PPP3R1,
PPP3R2 💬		33件: Alzheimer disease, Amphetamine addiction, Amyotrophic lateral sclerosis, Axon guidance, B cell receptor signaling pathway, C-type lectin receptor signaling pathway, Calcium signaling pathway, Cellular senescence, Dopaminergic synapse, Glucagon signaling pathway, Glutamatergic synapse, Human T-cell leukemia virus 1 infection, Human cytomegalovirus infection, Human immunodeficiency virus 1 infection, Kaposi sarcoma-associated herpesvirus infection, Lipid and atherosclerosis, Long-term potentiation, MAPK signaling pathway, Natural killer cell mediated cytotoxicity, Oocyte meiosis, Osteoclast differentiation, Oxytocin signaling pathway, PD-L1 expression and PD-1 checkpoint pathway in cancer, Pathways of neurodegeneration - multiple diseases, Prion disease, Renin secretion, T cell receptor signaling pathway, Th1 and Th2 cell differentiation, Th17 cell differentiation, Tuberculosis, VEGF signaling pathway, Wnt signaling pathway, cGMP-PKG signaling pathway 💬1件: 60
127Other: Cysteamine bitartrate1件: Cysteamine2件: D03634 ,
D03635 		--1件: 19
128Other: D-xylose1件: Xylose1件: D06346 --1件: 98
129Other: D5W----1件: 222
130Other: Data Capture1件: Bifenthrin---1件: 6
131Other: De-implementation of Inhaled Nitric Oxide (iNO) use1件: Nitric Oxide1件: D00074 --1件: 294
132Other: Dead Sea Solar and Water Treatment1件: Water1件: D00001 --1件: 46
133Other: Determination of calcium intake by a dietician interview1件: Calcium---2件: 13, 46
134Other: dextrose water 5%2件: Dextrose, unspecified form,
Water		1件: D00001 --1件: 56
135Other: diagnostic laboratory biomarker analysis----1件: 74
136Other: Diagnostics for glucose tolerance with 3 different methods.1件: Dextrose, unspecified form---1件: 299
137Other: Diary completion----1件: 6
138Other: Diet----1件: 240
139Other: Diet treatment----1件: 240
140Other: Diet-CD----1件: 96
141Other: dietary intervention with no-carrageenan diet----1件: 97
142Other: Dietary recommendations----1件: 51
143Other: Digestible Maltodextrin1件: Maltodextrin1件: D02329 --1件: 96
144Other: Discontinuation of dornase alfa (dnase)1件: Dornase alfa1件: D03896 --1件: 299
145Other: Discontinuation of hypertonic saline (HS)----1件: 299
146Other: DMT withdrawal----1件: 13
147Other: dobutamine1件: Dobutamine4件: D00632 ,
D03879 ,
D03880 ,
D03881 		1件: ADRB1 💬11件: Adrenergic signaling in cardiomyocytes, Calcium signaling pathway, Chemical carcinogenesis - receptor activation, Dilated cardiomyopathy, Gap junction, Neuroactive ligand-receptor interaction, Regulation of lipolysis in adipocytes, Renin secretion, Salivary secretion, cAMP signaling pathway, cGMP-PKG signaling pathway 💬1件: 215
148Other: Donor derived G-CSF mobilized PBC1件: Filgrastim1件: D03235 1件: CSF3R 💬5件: Cytokine-cytokine receptor interaction, Hematopoietic cell lineage, JAK-STAT signaling pathway, PI3K-Akt signaling pathway, Pathways in cancer 💬1件: 60
149Other: Donor Lymphocyte Infusion----1件: 65
150Other: Dosage of Delta-aminolevulinic acid and Porphobilinogen2件: Aminolevulinic acid,
Porphobilinogen		2件: D02908 ,
D07567 		--1件: 254
151Other: Dose reduction to 2mg/L----1件: 46
152Other: Dose reduction to 5mg/L----1件: 46
153Other: Dried blood spot test for MPS----1件: 19
154Other: Drug free----1件: 49
155Other: Dual Task Performance----1件: 13
156Other: Dummy Tripterygium wilfordii Hook F (TwHF)1件: Tripterygium wilfordii whole---1件: 46
157Other: Dynamic Balance Training1件: Isoxaflutole---1件: 13
158Other: Dynamic balance walking training1件: Isoxaflutole---1件: 13
159Other: Dystrophin levels----1件: 113
160Other: DYT 1 Dystonia----1件: 6
161Other: DYT 1 Dystonia (Healthy Control)----1件: 6
162Other: e-Monitoring----1件: 97
163Other: Eating Assessment Tool 10----1件: 2
164Other: Eating Assessment Tool-10----1件: 2
165Other: Echocardiogram----1件: 113
166Other: Eculizumab1件: Eculizumab1件: D03940 1件: C5 💬10件: Alcoholic liver disease, Complement and coagulation cascades, Coronavirus disease - COVID-19, Herpes simplex virus 1 infection, Neuroactive ligand-receptor interaction, Neutrophil extracellular trap formation, Pertussis, Prion disease, Staphylococcus aureus infection, Systemic lupus erythematosus 💬1件: 109
167Other: EEnG Questionnaire----1件: 291
168Other: EIT----1件: 228
169Other: Electroencephalogram (EEG) awake andextended overnight----1件: 19
170Other: Elektro-Entero-Graphy procedure----1件: 291
171Other: Elimination diet----1件: 98
172Other: Empiric use of Calcium Carbonate and Calcitriol3件: Calcitriol,
Calcium,
Carbonate ion		1件: D00129 1件: VDR 💬5件: Chemical carcinogenesis - receptor activation, Endocrine and other factor-regulated calcium reabsorption, Mineral absorption, Parathyroid hormone synthesis, secretion and action, Tuberculosis 💬1件: 235
173Other: Endurance----1件: 6
174Other: enteral nutrition----1件: 96
175Other: Epiduroscopy----1件: 70
176Other: Epistaxis charts----1件: 227
177Other: EUS procedure----1件: 298
178Other: Evaluation by Investigator----1件: 6
179Other: Evaluation of degree chronic fatigue.----1件: 13
180Other: Event-related evoked potential using electroencephalography (EEG).----1件: 6
181Other: Exclusion Diet----1件: 96
182Other: Exclusive enteral nutrition----1件: 96
183Other: Exclusive Enteral Nutrition (EEN)----1件: 96
184Other: Exercise capacity----1件: 299
185Other: Exercise echocardiography----1件: 58
186Other: Exercise followed cold water immersion1件: Water1件: D00001 --1件: 46
187Other: Exercise intervention----2件: 13, 18
188Other: Exposure to methylprednisolone during pregnancy1件: Methylprednisolone6件: D00407 ,
D00751 ,
D00979 ,
D05000 ,
D05001 ,
D05002 		1件: NR3C1 💬1件: Neuroactive ligand-receptor interaction 💬1件: 13
189Other: Extracorporeal Photopheresis (ECP) with Methoxsalen1件: Methoxsalen1件: D00139 --1件: 51
190Other: Faecal bacterial transplantation----1件: 97
191Other: Fast Mimicking Diet----1件: 97
192Other: fatigue----1件: 13
193Other: Fear of falling----1件: 13
194Other: fingolimod1件: Fingolimod1件: D10001 1件: S1PR1 💬3件: FoxO signaling pathway, Neuroactive ligand-receptor interaction, Sphingolipid signaling pathway 💬1件: 13
195Other: Fitbit Activity Monitor1件: Methamidophos---1件: 49
196Other: flow cytometry----3件: 28, 51, 60
197Other: Fluid Restriction----1件: 72
198Other: Fluorescein angiography1件: Fluorescein2件: D01261 ,
D02024 		--1件: 19
199Other: fog----1件: 6
200Other: Follow-up study of the untreated cohort----1件: 193
201Other: Food Diary----1件: 65
202Other: Four Square Step Test----2件: 6, 13
203Other: Fractional Exhaled NO (FENO)----1件: 96
204Other: Fresh Frozen Plasma----1件: 14
205Other: Fruit juice----1件: 299
206Other: Functional involvement of identified epigenetic alterations----1件: 102
207Other: Functional mobility----2件: 6, 13
208Other: Functional Oral Intake Scale----1件: 2
209Other: Functional Reach Test----2件: 6, 13
210Other: Gadobutrol1件: Gadobutrol1件: D07420 --1件: 46
211Other: Gait and balance group training1件: Isoxaflutole---1件: 6
212Other: General and Neurological examination----1件: 19
213Other: general population----2件: 46, 271
214Other: Generation of Induced Pluripotent Stem Cells (iPSC) from fibroblasts obtained by skin biopsy----1件: 102
215Other: Genetic data/DNA/RNA----3件: 49, 51, 85
216Other: GH pause----1件: 78
217Other: GHRH plus arginine test2件: Arginine,
Somatorelin		2件: D02982 ,
D08523 		1件: GHRHR 💬2件: Growth hormone synthesis, secretion and action, Neuroactive ligand-receptor interaction 💬1件: 78
218Other: GHRH+Arg, GHRH+Arg, ITT1件: Somatorelin1件: D08523 1件: GHRHR 💬2件: Growth hormone synthesis, secretion and action, Neuroactive ligand-receptor interaction 💬1件: 78
219Other: Glucose1件: Dextrose, unspecified form---1件: 254
220Other: Glucose -potentiated arginine (GPA) stimulation tests2件: Arginine,
Dextrose, unspecified form		1件: D02982 --1件: 299
221Other: Glucose profile for 2 weeks1件: Dextrose, unspecified form---1件: 299
222Other: glucose solution at a dose of 1.75 g/kg (up to a maximum of 75 g) for the OGTT and glucose solution at a dose of 0.5 g/kg (up to a maximum of 35 g) was injected in 2.5-3 min for the IGTT1件: Dextrose, unspecified form---1件: 299
223Other: Glycerine gel1件: Glycerin1件: D00028 --1件: 265
224Other: Gold Standard Questionnaire1件: Gold---1件: 291
225Other: Green tea (Camellia sinensis)1件: Green tea leaf1件: D06903 --1件: 96
226Other: Groningen Anti-Inflammatory Diet (GrAID)----1件: 96
227Other: Group 2 (DMARDS treated group)----1件: 46
228Other: Group B SLE one blood donation----1件: 49
229Other: Group balance training1件: Isoxaflutole---1件: 13
230Other: Group Exercise: community setting----1件: 70
231Other: Growth hormone1件: Somatotropin1件: D02691 1件: GHR 💬5件: Cytokine-cytokine receptor interaction, Growth hormone synthesis, secretion and action, JAK-STAT signaling pathway, Neuroactive ligand-receptor interaction, PI3K-Akt signaling pathway 💬1件: 78
232Other: GSK2586184 single dose taken with food----1件: 49
233Other: GSK2586184 single dose taken without food----1件: 49
234Other: Haematopoietic Stem Cell Transplantation (HSCT)----1件: 65
235Other: Hand training----1件: 46
236Other: Harkány medicinal water1件: Water1件: D00001 --1件: 46
237Other: healthy controls----1件: 63
238Other: Healthy volunteers----1件: 46
239Other: hemicellulose crystalline----1件: 6
240Other: Hepatic elastography----1件: 299
241Other: High energy / protein diet.----1件: 96
242Other: High Glycemic Index Meal----1件: 299
243Other: High intensity exercise and balance training1件: Isoxaflutole---1件: 6
244Other: high performance liquid chromatography----1件: 96
245Other: High resolution peripheral quantitative computed tomography (HRpQCT)----1件: 172
246Other: High Water Intake1件: Water1件: D00001 --1件: 67
247Other: High-impact exercise intervention----1件: 96
248Other: High-intensity training in shallow and deep water1件: Water1件: D00001 --1件: 6
249Other: Histamine1件: Histamine1件: D08040 4件: HRH1,
HRH2,
HRH3,
HRH4 💬		4件: Calcium signaling pathway, Gastric acid secretion, Inflammatory mediator regulation of TRP channels, Neuroactive ligand-receptor interaction 💬1件: 13
250Other: Histone acetylation profiles of cells of SRT patients with CREBBP mutations----1件: 102
251Other: Historical control----1件: 2
252Other: Hoehn and Yahr Scale----1件: 6
253Other: Home functional balance physiotherapy1件: Isoxaflutole---1件: 6
254Other: Honey1件: Honey1件: D06776 --1件: 98
255Other: Human Milk Derived Fortifier1件: Cow milk---1件: 210
256Other: Human umbilical cord-derived MSCs and cyclosporin A1件: Cyclosporine1件: D00184 5件: PPP3CA,
PPP3CB,
PPP3CC,
PPP3R1,
PPP3R2 💬		33件: Alzheimer disease, Amphetamine addiction, Amyotrophic lateral sclerosis, Axon guidance, B cell receptor signaling pathway, C-type lectin receptor signaling pathway, Calcium signaling pathway, Cellular senescence, Dopaminergic synapse, Glucagon signaling pathway, Glutamatergic synapse, Human T-cell leukemia virus 1 infection, Human cytomegalovirus infection, Human immunodeficiency virus 1 infection, Kaposi sarcoma-associated herpesvirus infection, Lipid and atherosclerosis, Long-term potentiation, MAPK signaling pathway, Natural killer cell mediated cytotoxicity, Oocyte meiosis, Osteoclast differentiation, Oxytocin signaling pathway, PD-L1 expression and PD-1 checkpoint pathway in cancer, Pathways of neurodegeneration - multiple diseases, Prion disease, Renin secretion, T cell receptor signaling pathway, Th1 and Th2 cell differentiation, Th17 cell differentiation, Tuberculosis, VEGF signaling pathway, Wnt signaling pathway, cGMP-PKG signaling pathway 💬1件: 60
257Other: Human/Bovine Milk1件: Cow milk---1件: 210
258Other: Hydrocortisone1件: Hydrocortisone1件: D00088 1件: NR3C1 💬1件: Neuroactive ligand-receptor interaction 💬1件: 75
259Other: Hydrogen peroxide2件: Hydrogen,
Hydrogen peroxide		1件: D00008 --1件: 13
260Other: Hydroxychloroquine/Chloroquine2件: Chloroquine,
Hydroxychloroquine		4件: D02125 ,
D02366 ,
D03469 ,
D08050 		--1件: 46
261Other: Hyperbaric oxygen1件: Oxygen1件: D00003 --1件: 96
262Other: Hyperbaric Oxygen Therapy1件: Oxygen1件: D00003 --2件: 97, 226
263Other: Hyperpolarized Xenon MRI1件: Xenon2件: D01901 ,
D06339 		--1件: 299
264Other: Hypoglycemic Clamp----1件: 299
265Other: Hypothyroidism QOL questionnaire----1件: 80
266Other: Ibuprofen and Isosorbide Dinitrate combination2件: Ibuprofen,
Isosorbide dinitrate		5件: D00126 ,
D00516 ,
D01122 ,
D04490 ,
D06606 		2件: PTGS1,
PTGS2 💬		23件: Alzheimer disease, Arachidonic acid metabolism, C-type lectin receptor signaling pathway, Chemical carcinogenesis - DNA adducts, Human cytomegalovirus infection, Human papillomavirus infection, IL-17 signaling pathway, Kaposi sarcoma-associated herpesvirus infection, Leishmaniasis, Metabolic pathways, MicroRNAs in cancer, NF-kappa B signaling pathway, Ovarian steroidogenesis, Oxytocin signaling pathway, Pathways in cancer, Pathways of neurodegeneration - multiple diseases, Platelet activation, Regulation of lipolysis in adipocytes, Retrograde endocannabinoid signaling, Serotonergic synapse, Small cell lung cancer, TNF signaling pathway, VEGF signaling pathway 💬1件: 113
267Other: Iloprost (Ventavis inhaled, BAYQ6256)1件: Iloprost1件: D02721 1件: PTGIR 💬3件: Neuroactive ligand-receptor interaction, Platelet activation, Vascular smooth muscle contraction 💬1件: 86
268Other: Imaging----1件: 13
269Other: Imitation Surgical Procedure (ISP)----1件: 6
270Other: immunologic technique----1件: 49
271Other: Impact of biotherapy on postoperative morbidity in ulcerative colitis----1件: 97
272Other: Impact Peptide 1.5----1件: 299
273Other: inactive drug----1件: 226
274Other: Incontinence Severity----1件: 13
275Other: Individualized exercises: clinical setting----1件: 70
276Other: Induced hypotonic hyponatremia - SIAD model----1件: 72
277Other: infliximab (IFX) infusion1件: Infliximab1件: D02598 1件: TNF 💬67件: AGE-RAGE signaling pathway in diabetic complications, Adipocytokine signaling pathway, African trypanosomiasis, Alcoholic liver disease, Allograft rejection, Alzheimer disease, Amoebiasis, Amyotrophic lateral sclerosis, Antifolate resistance, Antigen processing and presentation, Apoptosis, Asthma, C-type lectin receptor signaling pathway, Chagas disease, Coronavirus disease - COVID-19, Cytokine-cytokine receptor interaction, Dilated cardiomyopathy, Epstein-Barr virus infection, Fc epsilon RI signaling pathway, Fluid shear stress and atherosclerosis, Graft-versus-host disease, Hematopoietic cell lineage, Hepatitis B, Hepatitis C, Herpes simplex virus 1 infection, Human T-cell leukemia virus 1 infection, Human cytomegalovirus infection, Human immunodeficiency virus 1 infection, Human papillomavirus infection, Hypertrophic cardiomyopathy, IL-17 signaling pathway, Inflammatory bowel disease, Influenza A, Insulin resistance, Legionellosis, Leishmaniasis, Lipid and atherosclerosis, MAPK signaling pathway, Malaria, NF-kappa B signaling pathway, NOD-like receptor signaling pathway, Natural killer cell mediated cytotoxicity, Necroptosis, Non-alcoholic fatty liver disease, Osteoclast differentiation, Pathogenic Escherichia coli infection, Pathways of neurodegeneration - multiple diseases, Pertussis, Prion disease, Proteoglycans in cancer, RIG-I-like receptor signaling pathway, Rheumatoid arthritis, Salmonella infection, Shigellosis, Sphingolipid signaling pathway, Systemic lupus erythematosus, T cell receptor signaling pathway, TGF-beta signaling pathway, TNF signaling pathway, Toll-like receptor signaling pathway, Toxoplasmosis, Tuberculosis, Type I diabetes mellitus, Type II diabetes mellitus, Viral protein interaction with cytokine and cytokine receptor, Yersinia infection, mTOR signaling pathway 💬1件: 96
278Other: Inhalable Hypertonic saline 7%----1件: 299
279Other: Inhalable Hypertonic saline 7% + Hyaluronan 0.1%1件: Hyaluronic acid1件: D08043 --1件: 299
280Other: Inhaled Hyperpolarized Xenon-1291件: Xenon2件: D01901 ,
D06339 		--1件: 228
281Other: Intensify treatment with the existing drug----2件: 96, 97
282Other: intensive supportive care----1件: 66
283Other: Intrathecal saline injection----1件: 13
284Other: ISA 51----1件: 50
285Other: ISA 51 VG----1件: 49
286Other: ITT, ITT, GHRH+Arg.1件: Somatorelin1件: D08523 1件: GHRHR 💬2件: Growth hormone synthesis, secretion and action, Neuroactive ligand-receptor interaction 💬1件: 78
287Other: IV saline infusion----1件: 96
288Other: IV steroids combination alone----1件: 41
289Other: IVIg1件: Human immunoglobulin G---1件: 35
290Other: Joint Mobilizations (spine, sacroiliac, hip)----1件: 70
291Other: Kesimpta1件: Ofatumumab1件: D09314 1件: MS4A1 💬1件: Hematopoietic cell lineage 💬1件: 13
292Other: Ketogenic Diet----2件: 19, 67
293Other: Lab Work----1件: 46
294Other: Laboratory Biomarker Analysis----21件: 11, 13, 14, 26, 28, 34, 49, 51, 60, 62, 65, 89, 96, 97, 205, 232, 283, 284, 285, 298, 331
295Other: Language Intervention----1件: 206
296Other: Lengthening adalimumab dosing interval1件: Adalimumab1件: D02597 1件: TNF 💬67件: AGE-RAGE signaling pathway in diabetic complications, Adipocytokine signaling pathway, African trypanosomiasis, Alcoholic liver disease, Allograft rejection, Alzheimer disease, Amoebiasis, Amyotrophic lateral sclerosis, Antifolate resistance, Antigen processing and presentation, Apoptosis, Asthma, C-type lectin receptor signaling pathway, Chagas disease, Coronavirus disease - COVID-19, Cytokine-cytokine receptor interaction, Dilated cardiomyopathy, Epstein-Barr virus infection, Fc epsilon RI signaling pathway, Fluid shear stress and atherosclerosis, Graft-versus-host disease, Hematopoietic cell lineage, Hepatitis B, Hepatitis C, Herpes simplex virus 1 infection, Human T-cell leukemia virus 1 infection, Human cytomegalovirus infection, Human immunodeficiency virus 1 infection, Human papillomavirus infection, Hypertrophic cardiomyopathy, IL-17 signaling pathway, Inflammatory bowel disease, Influenza A, Insulin resistance, Legionellosis, Leishmaniasis, Lipid and atherosclerosis, MAPK signaling pathway, Malaria, NF-kappa B signaling pathway, NOD-like receptor signaling pathway, Natural killer cell mediated cytotoxicity, Necroptosis, Non-alcoholic fatty liver disease, Osteoclast differentiation, Pathogenic Escherichia coli infection, Pathways of neurodegeneration - multiple diseases, Pertussis, Prion disease, Proteoglycans in cancer, RIG-I-like receptor signaling pathway, Rheumatoid arthritis, Salmonella infection, Shigellosis, Sphingolipid signaling pathway, Systemic lupus erythematosus, T cell receptor signaling pathway, TGF-beta signaling pathway, TNF signaling pathway, Toll-like receptor signaling pathway, Toxoplasmosis, Tuberculosis, Type I diabetes mellitus, Type II diabetes mellitus, Viral protein interaction with cytokine and cytokine receptor, Yersinia infection, mTOR signaling pathway 💬1件: 96
297Other: Leukapheresis- Collection of stem cells----1件: 96
298Other: levothyroxine1件: Levothyroxine2件: D01010 ,
D08125 		2件: THRA,
THRB 💬		2件: Neuroactive ligand-receptor interaction, Thyroid hormone signaling pathway 💬1件: 78
299Other: Liberation therapy----1件: 13
300Other: Liquid Meal Test (Carbohydrate-rich)----1件: 299
301Other: Liquid Meal Test (Fat-rich)----1件: 299
302Other: Liquid Meal Test (Mixed)----1件: 299
303Other: Liver Evaluation----1件: 240
304Other: Liver questionnaire----1件: 231
305Other: Losartan1件: Losartan2件: D00357 ,
D08146 		1件: AGTR1 💬16件: AGE-RAGE signaling pathway in diabetic complications, Adrenergic signaling in cardiomyocytes, Aldosterone synthesis and secretion, Apelin signaling pathway, Calcium signaling pathway, Coronavirus disease - COVID-19, Cortisol synthesis and secretion, Cushing syndrome, Diabetic cardiomyopathy, Neuroactive ligand-receptor interaction, Pathways in cancer, Phospholipase D signaling pathway, Renin secretion, Renin-angiotensin system, Vascular smooth muscle contraction, cGMP-PKG signaling pathway 💬1件: 46
306Other: Low Blood Pressure Control----1件: 67
307Other: Low dose (1 mcg) ACTH stimulation test1件: Corticotropin1件: D00146 1件: MC2R 💬5件: Aldosterone synthesis and secretion, Cortisol synthesis and secretion, Cushing syndrome, Neuroactive ligand-receptor interaction, cAMP signaling pathway 💬1件: 193
308Other: Low Glycemic Index Meal----1件: 299
309Other: Low n-6 PUFA Diet----1件: 96
310Other: Low-intensity exercise therapy----1件: 298
311Other: Lower Limb Strength----1件: 6
312Other: Magnetic Resonance Imaging (MRI)----1件: 113
313Other: Mangafodipir trisodium1件: Mangafodipir1件: D08262 --1件: 58
314Other: Meal Challenge----1件: 240
315Other: measure of endothelial function----1件: 299
316Other: Measurement of drug (Adalimumab/Infliximab)2件: Adalimumab,
Infliximab		2件: D02597 ,
D02598 		1件: TNF 💬67件: AGE-RAGE signaling pathway in diabetic complications, Adipocytokine signaling pathway, African trypanosomiasis, Alcoholic liver disease, Allograft rejection, Alzheimer disease, Amoebiasis, Amyotrophic lateral sclerosis, Antifolate resistance, Antigen processing and presentation, Apoptosis, Asthma, C-type lectin receptor signaling pathway, Chagas disease, Coronavirus disease - COVID-19, Cytokine-cytokine receptor interaction, Dilated cardiomyopathy, Epstein-Barr virus infection, Fc epsilon RI signaling pathway, Fluid shear stress and atherosclerosis, Graft-versus-host disease, Hematopoietic cell lineage, Hepatitis B, Hepatitis C, Herpes simplex virus 1 infection, Human T-cell leukemia virus 1 infection, Human cytomegalovirus infection, Human immunodeficiency virus 1 infection, Human papillomavirus infection, Hypertrophic cardiomyopathy, IL-17 signaling pathway, Inflammatory bowel disease, Influenza A, Insulin resistance, Legionellosis, Leishmaniasis, Lipid and atherosclerosis, MAPK signaling pathway, Malaria, NF-kappa B signaling pathway, NOD-like receptor signaling pathway, Natural killer cell mediated cytotoxicity, Necroptosis, Non-alcoholic fatty liver disease, Osteoclast differentiation, Pathogenic Escherichia coli infection, Pathways of neurodegeneration - multiple diseases, Pertussis, Prion disease, Proteoglycans in cancer, RIG-I-like receptor signaling pathway, Rheumatoid arthritis, Salmonella infection, Shigellosis, Sphingolipid signaling pathway, Systemic lupus erythematosus, T cell receptor signaling pathway, TGF-beta signaling pathway, TNF signaling pathway, Toll-like receptor signaling pathway, Toxoplasmosis, Tuberculosis, Type I diabetes mellitus, Type II diabetes mellitus, Viral protein interaction with cytokine and cytokine receptor, Yersinia infection, mTOR signaling pathway 💬2件: 96, 97
317Other: Medical air2件: Medical air,
Oxygen		1件: D00003 --1件: 85
318Other: medical chart review----1件: 60
319Other: Medical History Questionnaires----1件: 65
320Other: Medication Compliance Phone Call----1件: 98
321Other: Mesalazine1件: Mesalazine1件: D00377 --1件: 97
322Other: Metabolic Exercise Testing using stationary bicycle----1件: 113
323Other: Metformin1件: Metformin2件: D00944 ,
D04966 		2件: PRKAA1,
PRKAA2 💬		20件: AMPK signaling pathway, Adipocytokine signaling pathway, Alcoholic liver disease, Apelin signaling pathway, Autophagy - animal, Circadian rhythm, Fluid shear stress and atherosclerosis, FoxO signaling pathway, Glucagon signaling pathway, Hypertrophic cardiomyopathy, Insulin resistance, Insulin signaling pathway, Longevity regulating pathway, Longevity regulating pathway - multiple species, Non-alcoholic fatty liver disease, Oxytocin signaling pathway, PI3K-Akt signaling pathway, Thermogenesis, Tight junction, mTOR signaling pathway 💬1件: 46
324Other: Methacholine Challenge Test1件: Methacholine---1件: 96
325Other: Methotrexate therapy1件: Methotrexate2件: D00142 ,
D02115 		2件: DHFR,
DHFR2 💬		5件: Antifolate resistance, Biosynthesis of cofactors, Folate biosynthesis, Metabolic pathways, One carbon pool by folate 💬1件: 46
326Other: MIBG label with I123 or I124----1件: 6
327Other: Microindentation----1件: 172
328Other: mitoxantrone - immunomodulator1件: Mitoxantrone2件: D02166 ,
D08224 		2件: TOP2A,
TOP2B 💬		1件: Platinum drug resistance 💬1件: 13
329Other: Mixed meal test evaluation test arm----1件: 299
330Other: Mixed Meal Tolerance Test----1件: 299
331Other: Mobile platform exercise----1件: 6
332Other: Mock injection----1件: 90
333Other: modified Atkins diet----1件: 145
334Other: Modified Mixed Meal Tolerance Test----1件: 65
335Other: Modified Oral Glucose Tolerance Test1件: Dextrose, unspecified form---1件: 65
336Other: Modified paleolithic diet----1件: 13
337Other: Monthly assessments of functional motor abilities by a trained therapist----1件: 3
338Other: Motor Assessments before taking regular PD treatment----1件: 6
339Other: Motor Assessments on regular PD treatment----1件: 6
340Other: MP+DDCI----1件: 6
341Other: MP-Equivalent----1件: 6
342Other: MP-Low----1件: 6
343Other: MPS I----1件: 19
344Other: MRI----3件: 6, 127, 206
345Other: MSCs----1件: 13
346Other: Multidisciplinary intensive rehabilitation treatment----1件: 6
347Other: Muscle oxygenation----1件: 299
348Other: Music----1件: 6
349Other: myBETAapp----1件: 13
350Other: N-thymidine1件: Thymidine---1件: 215
351Other: Natalizumab1件: Natalizumab1件: D06886 1件: ITGA4 💬14件: Arrhythmogenic right ventricular cardiomyopathy, Cell adhesion molecules, Dilated cardiomyopathy, ECM-receptor interaction, Focal adhesion, Hematopoietic cell lineage, Human papillomavirus infection, Hypertrophic cardiomyopathy, Intestinal immune network for IgA production, Leishmaniasis, Leukocyte transendothelial migration, PI3K-Akt signaling pathway, Regulation of actin cytoskeleton, Yersinia infection 💬1件: 13
352Other: Natalizumab discontinuation1件: Natalizumab1件: D06886 1件: ITGA4 💬14件: Arrhythmogenic right ventricular cardiomyopathy, Cell adhesion molecules, Dilated cardiomyopathy, ECM-receptor interaction, Focal adhesion, Hematopoietic cell lineage, Human papillomavirus infection, Hypertrophic cardiomyopathy, Intestinal immune network for IgA production, Leishmaniasis, Leukocyte transendothelial migration, PI3K-Akt signaling pathway, Regulation of actin cytoskeleton, Yersinia infection 💬1件: 13
353Other: natural herbs of coconut, aloe vera, and pepperint2件: Aloe vera leaf,
Coconut		---1件: 53
354Other: NBT-NM108 (0 g/day)----1件: 13
355Other: Neupro 4 mg / 24 Hr. Transdermal Patch1件: Rotigotine1件: D05768 1件: DRD2 💬8件: Alcoholism, Cocaine addiction, Dopaminergic synapse, Gap junction, Neuroactive ligand-receptor interaction, Parkinson disease, Rap1 signaling pathway, cAMP signaling pathway 💬1件: 6
356Other: Neurology exam----1件: 19
357Other: Neuromuscular evaluation----1件: 13
358Other: Nil per os----1件: 291
359Other: Nintendo Wii Fit Balance exercises1件: Isoxaflutole---1件: 13
360Other: No active treatment----1件: 274
361Other: No anti-inflammatory treatment----1件: 271
362Other: No device----1件: 13
363Other: No doxycycline1件: Doxycycline5件: D00307 ,
D02129 ,
D03903 ,
D03904 ,
D07876 		--1件: 299
364Other: No enzyme therapy----1件: 298
365Other: NO intervention----4件: 13, 70, 96, 97
366Other: No Intervention: Standard of Care----1件: 85
367Other: No IT treatment----1件: 19
368Other: No MSDMDs therapy (control)----1件: 13
369Other: No pancreatic enzyme replacement therapy----1件: 299
370Other: No Plasma Exchange----2件: 43, 44
371Other: No treatment----2件: 53, 274
372Other: No Treatment Arm----1件: 13
373Other: No treatment given----1件: 78
374Other: Non Impact Aerobics----1件: 13
375Other: Non-hormonal period----1件: 299
376Other: Non-Motor Symptoms----1件: 6
377Other: Noninvasive actigraphy monitor1件: Methamidophos---1件: 86
378Other: Nordic walking (only osteoporosis group)----1件: 6
379Other: Normal (control) diet----1件: 240
380Other: normal diet----1件: 96
381Other: normal saline----4件: 13, 222, 226, 280
382Other: Normal Saline for injection----1件: 84
383Other: NS----1件: 96
384Other: Numerical rating scale----1件: 46
385Other: Nutrition counseling----1件: 298
386Other: Obese----1件: 75
387Other: Observation----1件: 265
388Other: Observation of Ocrelizumab as Treatment in RRMS Patients1件: Ocrelizumab1件: D05218 1件: MS4A1 💬1件: Hematopoietic cell lineage 💬1件: 13
389Other: Observation Only----1件: 331
390Other: Observational----1件: 90
391Other: Observational cohort----1件: 6
392Other: Observational Control----1件: 13
393Other: Ocrelizumab1件: Ocrelizumab1件: D05218 1件: MS4A1 💬1件: Hematopoietic cell lineage 💬1件: 13
394Other: Ofatumumab1件: Ofatumumab1件: D09314 1件: MS4A1 💬1件: Hematopoietic cell lineage 💬1件: 13
395Other: OGTT----1件: 299
396Other: On-demand treatment----1件: 299
397Other: One-leg Stance Test----1件: 13
398Other: Ophthalmologic examinations----1件: 299
399Other: Optimized Supportive Care----1件: 66
400Other: Optimizing basal infusion (B.I)----1件: 70
401Other: Optional Blood-Oxygen-level Dependent functionalMRI1件: Oxygen1件: D00003 --1件: 6
402Other: Oral Glucose tolerance test1件: Dextrose, unspecified form---3件: 160, 195, 299
403Other: Oral Glucose Tolerance Test (OGTT) assessment arm1件: Dextrose, unspecified form---1件: 299
404Other: Oral Nitric Oxide testing1件: Nitric Oxide1件: D00074 --1件: 98
405Other: Other Biologic Agents----2件: 96, 97
406Other: Other biological samples to biobank (skin, lung and muscle biopsies----3件: 49, 51, 85
407Other: Other intervention(s)----1件: 70
408Other: Other: Disease modifying therapies (DMT)----1件: 13
409Other: Other: Symptomatic treatment of ALS----1件: 2
410Other: Outpatient rheumatology department----1件: 46
411Other: Overnight metyrapone test1件: Metyrapone2件: D00410 ,
D05019 		1件: CYP11B1 💬4件: Cortisol synthesis and secretion, Cushing syndrome, Metabolic pathways, Steroid hormone biosynthesis 💬1件: 193
412Other: Oxygen1件: Oxygen1件: D00003 --1件: 85
413Other: Oxygen (2Liter/min)1件: Oxygen1件: D00003 --1件: 85
414Other: Oxygen (4Liter/min)1件: Oxygen1件: D00003 --1件: 85
415Other: Oxygen - Air1件: Oxygen1件: D00003 --1件: 299
416Other: Oxygen Supplementation1件: Oxygen1件: D00003 --1件: 86
417Other: ozone therapy1件: Ozone---1件: 51
418Other: Packing----1件: 227
419Other: pain----1件: 13
420Other: Palliative Care----5件: 19, 65, 120, 160, 326
421Other: Parkinson mPower mobile application----1件: 6
422Other: Parts A/B: Sham Control----1件: 19
423Other: Passive : lecture series----1件: 13
424Other: PBO----1件: 162
425Other: PCDAI----1件: 96
426Other: PD exercise intervention----1件: 6
427Other: PD vitamin + exercise----1件: 6
428Other: PEAK----1件: 13
429Other: Peanut Butter1件: Peanut---1件: 13
430Other: Pentadecanoic acid (PA) and Triheptadecanoin (THA)----1件: 299
431Other: PENTASA (mesalamine/ 5-Aminosalicylic acid (5-ASA)2件: Aminosalicylic acid,
Mesalazine		2件: D00162 ,
D00377 		--1件: 97
432Other: Periodized exercise training----1件: 13
433Other: Peripheral Blood Stem Cells----2件: 60, 62
434Other: Pharmacogenomic Study----1件: 26
435Other: Pharmacokinetic analysis----1件: 49
436Other: Pharmacological Study----7件: 28, 34, 62, 74, 89, 232, 331
437Other: Phenylalanine (Phe)-restricted diet1件: Phenylalanine1件: D00021 --1件: 240
438Other: Physalis angulata ethanol extract1件: Ethanol4件: D00068 ,
D02798 ,
D04855 ,
D06542 		--1件: 51
439Other: Physical Function Performance Test----1件: 6
440Other: Physical Therapy----2件: 6, 70
441Other: Pittsburgh Compound B [11C]-PIB1件: Pittsburgh Compound B---1件: 6
442Other: Plant-based diet----1件: 46
443Other: plasticity-based computerized cognitive remediation program----1件: 13
444Other: PNF----1件: 13
445Other: Position Sense----1件: 13
446Other: Postoperative nausea and vomiting at 24 hour----1件: 235
447Other: Postoperative nausea and vomiting at 6 hour----1件: 235
448Other: Postoperative pain at 24 hour----1件: 235
449Other: Postoperative pain at 6 hour----1件: 235
450Other: Postoperative sore throat and hoarseness at 24 hour----1件: 235
451Other: Postoperative sore throat and hoarseness at 6 hour----1件: 235
452Other: Potable water1件: Water1件: D00001 --1件: 19
453Other: prednisone1件: Prednisone1件: D00473 1件: NR3C1 💬1件: Neuroactive ligand-receptor interaction 💬1件: 46
454Other: pretreatment antibiotics----1件: 97
455Other: Progressive exercise----1件: 13
456Other: propensity score----1件: 13
457Other: Prospective observational registry----1件: 3
458Other: PSP----1件: 13
459Other: PTH based Calcium Carbonate and Calcitriol repletion4件: Calcitriol,
Calcium,
Calcium carbonate,
Carbonate ion		3件: D00129 ,
D00932 ,
D10802 		1件: VDR 💬5件: Chemical carcinogenesis - receptor activation, Endocrine and other factor-regulated calcium reabsorption, Mineral absorption, Parathyroid hormone synthesis, secretion and action, Tuberculosis 💬1件: 235
460Other: Pulmonary Function Testing (PFT)----1件: 113
461Other: Pulmonary rehabilitation program----1件: 85
462Other: QALCIMUM questionnaire----2件: 13, 46
463Other: Quality of life assessment----1件: 122
464Other: Quality of Life questionnaire----1件: 19
465Other: Quality-of-Life Assessment----9件: 34, 36, 51, 62, 65, 96, 283, 286, 298
466Other: quercetin1件: Quercetin---1件: 299
467Other: Questionnaire Administration----4件: 16, 34, 51, 298
468Other: Questionnaires----5件: 6, 13, 41, 93, 96
469Other: Reaction Time and Postural Control----1件: 299
470Other: Real-time data capture app1件: Bifenthrin---1件: 46
471Other: Recommendation with regard to nutrition----1件: 6
472Other: Reduction group 1----1件: 46
473Other: Reduction group 2----1件: 46
474Other: Refered to general practice----1件: 46
475Other: Resistance Exercise Program----1件: 46
476Other: Review of past medical history, clinical exam, and electroencephalogram, polysomnography and urine samples of melatonin and pupillometry.1件: Melatonin1件: D08170 2件: MTNR1A,
MTNR1B 💬		2件: Circadian entrainment, Neuroactive ligand-receptor interaction 💬1件: 149
477Other: Rheumatoid Arthritis Impact of Disease questionnaire----1件: 46
478Other: Rhythmic Auditory Stimulation (RAS)----2件: 6, 13
479Other: Rhythmic Balance-Movement Training (rBMT)1件: Isoxaflutole---1件: 6
480Other: RMST----1件: 256
481Other: Rosemary essential oil1件: Rosemary---1件: 51
482Other: Rotigotine1件: Rotigotine1件: D05768 1件: DRD2 💬8件: Alcoholism, Cocaine addiction, Dopaminergic synapse, Gap junction, Neuroactive ligand-receptor interaction, Parkinson disease, Rap1 signaling pathway, cAMP signaling pathway 💬1件: 6
483Other: Routine----1件: 240
484Other: routine management----1件: 291
485Other: routine therapy----1件: 299
486Other: RP% Measurement by FCM as a Diagnostic Test for ITP----1件: 63
487Other: Salbutamol nebulisation and with CPAP1件: Salbutamol1件: D02147 1件: ADRB2 💬9件: Adrenergic signaling in cardiomyocytes, Calcium signaling pathway, Chemical carcinogenesis - receptor activation, Neuroactive ligand-receptor interaction, Regulation of lipolysis in adipocytes, Renin secretion, Salivary secretion, cAMP signaling pathway, cGMP-PKG signaling pathway 💬1件: 228
488Other: Saline----8件: 2, 6, 46, 97, 98, 256, 274, 301
489Other: Saline as a nasal spray----1件: 226
490Other: Saline solution----1件: 67
491Other: Saline solution.----1件: 67
492Other: Screening to prevent falls----1件: 6
493Other: secukinumab1件: Secukinumab1件: D09967 1件: IL17A 💬6件: Alcoholic liver disease, Cytokine-cytokine receptor interaction, IL-17 signaling pathway, Inflammatory bowel disease, Rheumatoid arthritis, Th17 cell differentiation 💬1件: 271
494Other: Serum calcium concentrations results1件: Calcium---1件: 235
495Other: serum levels of angiogenin, bFGF, VEGF1件: Basic Fibroblast Growth Factor---1件: 56
496Other: Sham----1件: 301
497Other: Sham (no implant)----1件: 90
498Other: Sham abdominal compression----1件: 17
499Other: Sham Comparator----1件: 299
500Other: Sham group----1件: 6
501Other: Sham procedure----1件: 90
502Other: Sham Surgery----1件: 6
503Other: Sham-procedure----2件: 90, 303
504Other: Sham-procedure (dose cohort 1&2 only)----2件: 90, 303
505Other: Simvastatin1件: Simvastatin1件: D00434 1件: HMGCR 💬4件: AMPK signaling pathway, Bile secretion, Metabolic pathways, Terpenoid backbone biosynthesis 💬1件: 46
506Other: Siponimod1件: Siponimod1件: D11460 2件: S1PR1,
S1PR5 💬		3件: FoxO signaling pathway, Neuroactive ligand-receptor interaction, Sphingolipid signaling pathway 💬1件: 13
507Other: SLE treatment----1件: 49
508Other: Smartphone Application----1件: 49
509Other: Smartphone-based balance exercises1件: Isoxaflutole---1件: 6
510Other: sodium chloride2件: Chloride ion,
Sodium chloride		1件: D02056 --1件: 51
511Other: Specific SL-therapy----1件: 6
512Other: specifically design 6 month resistance training program----1件: 13
513Other: Specimen Collection----1件: 215
514Other: Spinning grp----1件: 13
515Other: Sputum Sample----1件: 299
516Other: Squat-to-stand maneuver----1件: 58
517Other: Standard----1件: 67
518Other: Standard Blood Pressure Control----1件: 67
519Other: Standard care----1件: 227
520Other: standard immune suppression, oral----1件: 228
521Other: Standard nutrition----1件: 96
522Other: standard of care----7件: 13, 49, 64, 85, 96, 245, 246
523Other: Standard of care (SOC)----1件: 62
524Other: Standard of Care Sildenafil1件: Sildenafil2件: D02229 ,
D08514 		1件: PDE5A 💬3件: Metabolic pathways, Purine metabolism, cGMP-PKG signaling pathway 💬2件: 90, 301
525Other: Standard steroid treatment----1件: 113
526Other: Standard therapy----1件: 49
527Other: Standard Treatment----1件: 227
528Other: Standard treatment according to the Clinical protocols----3件: 49, 51, 235
529Other: Standard-of-care----1件: 86
530Other: Standardized meals----1件: 86
531Other: Standardized scales: MDS-UPDRS (Part II to IV) and RDRS----1件: 6
532Other: Static Balance Test1件: Isoxaflutole---1件: 13
533Other: Stem Cell Transplant----1件: 96
534Other: Sterile Normal Saline (0.9% NaCl)----1件: 231
535Other: sterile saline----1件: 46
536Other: Stool Sample----2件: 6, 299
537Other: Strength training----1件: 13
538Other: Strength training in shallow water and dry land1件: Water1件: D00001 --1件: 6
539Other: Subacute hypoxic exposures----1件: 86
540Other: Subconjunctival injection of saline----1件: 90
541Other: Subcortical Stimulation----1件: 6
542Other: Sugar pill----1件: 90
543Other: Sulfur Pool & Medicinal Mud----1件: 46
544Other: Supervised physical therapy----1件: 13
545Other: Surgery----2件: 74, 96
546Other: Swallowing Quality of Life Questionnaire----1件: 2
547Other: Swallowing Related Quality of Life Questionnaire----1件: 2
548Other: Symptom Survey----1件: 98
549Other: Symptomatic hypocalcaemia at 24 hour----1件: 235
550Other: Symptomatic hypocalcaemia at 6 hour----1件: 235
551Other: Symptomatic therapy----1件: 160
552Other: t-DCS group----1件: 6
553Other: Tampa Kinesiophobia Scale, Berg-Balance Test, International Physical Activity Questionnaire-Short Form, Falls Efficacy Scale1件: Isoxaflutole---1件: 6
554Other: Technetium [Tc-99m] sulfur colloid and Indium [In-111] DTPA2件: Indium,
Pentetic acid		1件: D05422 --1件: 299
555Other: Telerehabilitation Based Functional Balance and Mobility Exercise1件: Isoxaflutole---1件: 6
556Other: Telerehabilitation Based LSVT BIG Exercise Protocol----1件: 6
557Other: Test Soda----1件: 299
558Other: The Center for Neurologic Studies Bulbar Function Scale----1件: 2
559Other: The Center for Neurologic Study Bulbar Function Scale----1件: 2
560Other: The patients' parents have to complete the VINELAND II adaptive behavior scales scoring, The Sleep Disturbance Scale for Children (SDSC) and Horne & Ostberg Circadian Typology Questionnaire----1件: 149
561Other: the timed 360° turn test----1件: 6
562Other: Therapy Education----1件: 97
563Other: Threonine1件: Threonine1件: D00041 --2件: 96, 97
564Other: Timed Up an Go Test----1件: 13
565Other: Timed Up and Go Test----1件: 6
566Other: Tobacco questionnaire1件: Tobacco leaf---1件: 299
567Other: Tobramycin time of administration1件: Tobramycin2件: D00063 ,
D02542 		--1件: 299
568Other: Training groupe----1件: 13
569Other: Transthoracic echocardiography at rest, during PLR, HG and CPX (including blood gas analysis in both groups). Additionally Fallot patients will undergo routine blood testings.----1件: 215
570Other: triangular test----1件: 96
571Other: Trunk impairment----1件: 13
572Other: Trunk Impairment Scale----1件: 6
573Other: Trunk position sense----1件: 13
574Other: tyramine1件: Tyramine---1件: 6
575Other: UC-MSCs by peripheral intravenous infusion1件: Human Umbilical Cord Mesenchymal Stem Cells---1件: 96
576Other: Ulcerative Colitis Diet----1件: 97
577Other: Ultrasonography assessment----1件: 49
578Other: Unified Parkinson's Disease Rating Scale----1件: 6
579Other: Untreated Cohort----1件: 85
580Other: Untreated contemporaneous cohort----1件: 118
581Other: Urine Collection----1件: 215
582Other: Use of a postpartum diary and additional blood draws----1件: 288
583Other: Use of a postpartum diary and additional blood draws.----1件: 288
584Other: USPIO MRI - Gadolinium MRI1件: Gadolinium---1件: 13
585Other: Usual care----3件: 46, 107, 299
586Other: Usual care arm exercise----1件: 6
587Other: Usual drug treatment of Parkinson's disease----1件: 6
588Other: Valsalva----1件: 58
589Other: Vegan Diet----1件: 46
590Other: Vegetable Oil----1件: 257
591Other: Vehicle----1件: 160
592Other: Vehicle (D5W or saline)----1件: 66
593Other: Vestibular habituation exercises----1件: 13
594Other: Vestibular rehabilitation: balance and eye movement exercises1件: Isoxaflutole---1件: 13
595Other: Virtual reality group----1件: 13
596Other: Visual Acuity (VA)----2件: 90, 301
597Other: Vital signs----1件: 19
598Other: Vitamin K1件: Phylloquinone1件: D00148 --1件: 13
599Other: Vitamin K Cream1件: Phylloquinone1件: D00148 --1件: 13
600Other: Voluntary cough test----1件: 6
601Other: Walk distance test----1件: 58
602Other: Water1件: Water1件: D00001 --1件: 67
603Other: Water prescription1件: Water1件: D00001 --1件: 67
604Other: Wheat flour1件: Wheat1件: D06902 --1件: 266
605Other: Withdrawal from alpha1 antitrypsin replacement therapy----1件: 231
606Other: Withdrawal of dalfampridine-ER 10mg1件: Dalfampridine1件: D04127 4件: KCNA4,
KCNC3,
KCND2,
KCND3 💬		4件: Cortisol synthesis and secretion, Cushing syndrome, Serotonergic synapse, Spinocerebellar ataxia 💬1件: 13
607Other: Xanthan Gum1件: Xanthan gum1件: D06333 --1件: 98